NCT07232420

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors.

Detailed description

The study consists of two phases: a dose escalation phase (Phase Ia) and a dose expansion phase (Phase Ib).

Conditions

• Non Small Cell Lung Cancer
• Solid Tumor

Interventions

Type	Name	Description
DRUG	BL-M24D1	Administration by intravenous infusion for a cycle of 2 weeks.

Timeline

• Start date: 2025-11-11
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-11-18
• Last updated: 2025-11-24

Locations

1 site across 1 country: China